🔬 Training Transformers to solve 95% failure rate of Cancer Trials — Ron Alfa & Daniel Bear, Noetik

Noetic aims to address the 95% failure rate of cancer drugs by improving patient selection through advanced AI models that analyze patient biology. By leveraging multimodal data, they seek to identify distinct cancer subtypes and match them with effective treatments, moving beyond traditional cell line testing. This innovative approach could revolutionize drug development and enhance the success of clinical trials.

Gain insights into how AI can transform cancer treatment by improving patient selection and drug efficacy.

1. 01The majority of cancer drug failures are attributed to poor patient selection rather than pharmacological issues.
2. 02Noetic's models can predict which patient populations will respond to specific drugs, potentially rescuing failing trials.
3. 03The understanding of cancer subtypes is evolving, with Noetic suggesting that existing classifications may overlook critical distinctions in patient biology.